My account
Injectables Orals Peptides Human Growth Hormone SARMs
Sign in
A
Anastrozole
B
Bacteriostatic water Boldenone undecylenate
C
Clenbuterol Clomiphene citrate Cabergoline
D
Drostanolone enanthate Drostanolone propionate Dehydroepiandrosterone (DHEA)
E
Erythropoietin Exemestane
F
Fluoxymesterone
H
Human chorionic gonadotropin Human growth hormone (HGH)
L
Liothyronine sodium
M
Mecasermin Meldonium Mesterolone Methandienone Methenolone acetate Methenolone enanthate Melanotan-2
N
Nandrolone decanoate Nandrolone phenylpropionate
O
Oxandrolone Oxymetholone
S
Sildenafil citrate Stanozolol
T
Trenbolone enanthate Trestolone acetate Trenbolone acetate Testosterone undecanoate Testosterone propionate Testosterone base and suspension Tadalafil citrate Testosterone cypionate Testosterone enanthate Tamoxifen citrate Turinabol
Y
Yohimbine
Show 164 results
Manufacturers
Categories
Substances
Disagree
Home Driada Medical Driada Medical
Stenobolic
Stenobolic - Driada Medical

Stenobolic - Driada Medical

Brand:
Driada Medical
Category:
SARMs
Substance:
Stenabolic
Dosage:
10 mg/tab
Package:
50 tablets
Price:
$43.00 - $4,565.00
See options
Product Overview
SR9009, also known as Stenabolic, was initially formulated to activate REV-ERB receptors but has since been identified as a potential therapeutic for prostate cancer (PCa). Its anticancer effects are mediated through the LXRα/FOXM1 pathway, a crucial axis in the proliferation and migration of PCS1 tumor cells. Experimental studies show that SR9009 effectively reduces tumor growth and metastasis by suppressing the expression of key genes linked to PCa aggressiveness while sparing non-cancerous prostate cells, highlighting its targeted action and safety profile .
References:

Xu, H., Zhang, J., Zheng, X., Tan, P., Xiong, X., Yi, X., Yang, Y., Wang, Y., Liao, D., Li, H., Wei, Q., Ai, J. and Yang, L., 2022. SR9009 inhibits lethal prostate cancer subtype 1 by regulating the LXRα/FOXM1 pathway independently of REV-ERBs. Cell Death & Disease.

Disclaimer: Information provided it this page is for general information only and does not substitute for professional medical advice.

For detailed information about Stenobolic by Driada Medical, consult with your doctor or healthcare professional.

Products
Active Substances
  • Stenabolic
Common Names
  • SR9009
 About Product
Stenobolic (SR-9009) 10 mg/50 tabs Driada Medical
Driada Medical
International
$43.00
Active Substances
  • Stenabolic
Common Names
  • SR9009
 About Product
Stenobolic (SR-9009) 10 mg/50 tabs Driada Medical
Driada Medical
Europe
$43.00
Active Substances
  • Stenabolic
Common Names
  • SR9009
 About Product
Stenobolic SR-9009 Driada Medical 10mg/tab/50tabs
Driada Medical
Europe
$53.00
Active Substances
  • Stenabolic
Common Names
  • SR9009
 About Product
Stenobolic (SR-9009) – 10mg – 50 Comprimés
Driada Medical
Europe
$4,565.00
Show more
Explore More Products
Reviews
Leave Review
FAQ
How does SR9009 differ from traditional cancer therapies?
It targets the LXRα/FOXM1 pathway rather than androgen receptors, reducing hormonal side effects.
References:

Xu, H., Zhang, J., Zheng, X., Tan, P., Xiong, X., Yi, X., Yang, Y., Wang, Y., Liao, D., Li, H., Wei, Q., Ai, J. and Yang, L., 2022. SR9009 inhibits lethal prostate cancer subtype 1 by regulating the LXRα/FOXM1 pathway independently of REV-ERBs. Cell Death & Disease.

What specific gene pathway does it affect?
The LXRα/FOXM1 pathway, which is critical in PCS1 prostate cancer aggressiveness.
References:

Xu, H., Zhang, J., Zheng, X., Tan, P., Xiong, X., Yi, X., Yang, Y., Wang, Y., Liao, D., Li, H., Wei, Q., Ai, J. and Yang, L., 2022. SR9009 inhibits lethal prostate cancer subtype 1 by regulating the LXRα/FOXM1 pathway independently of REV-ERBs. Cell Death & Disease.

Are there systemic side effects with SR9009?
Preclinical studies report minimal systemic toxicity, indicating a favorable safety profile.
References:

Xu, H., Zhang, J., Zheng, X., Tan, P., Xiong, X., Yi, X., Yang, Y., Wang, Y., Liao, D., Li, H., Wei, Q., Ai, J. and Yang, L., 2022. SR9009 inhibits lethal prostate cancer subtype 1 by regulating the LXRα/FOXM1 pathway independently of REV-ERBs. Cell Death & Disease.